REDMOND, Wash.–(BUSINESS WIRE)–November 21, 2017–
Gluco-Chaser Inc (www.Gluco-Chaser.com) releases a working prototype for non-enzymatic electrochemical glucose sensors. Built using proprietary technologies that have been optimized for over a decade, Gluco-ChaserTM offers multiple advantages over existing glucose sensors available in the market. The Gluco-ChaserTM offers flexibility in choosing a platform format, cost savings in production and storage (highly affordable end user pricing), and other technical features that improve user comfort level and hygiene. Gluco-ChaserTM CGM can be used daily for extended periods of time, which is useful for management of both Type 1 and Type 2 diabetes.
Proprietary non-enzymatic electrochemical glucose sensor: Gluco-ChaserTM employs a non-enzymatic electrochemical sensing scheme. It is the first of its kind, and has long been optimized for mass production since its introduction through a highly cited journal publication. The glucose detection mechanism and the corresponding electrode preparation methods are proprietary.
Business Benefits: Unlike most glucose sensors, Gluco-ChaserTM does not require an unstable and expensive enzyme for glucose detection. This leads to huge cost savings in production and storage of the core sensing components. Gluco-ChaserTM technology is applicable to various formats of glucose monitors from conventional BGM to short-term (8 ~ 48 hours)- and long-term (3 ~ 7 days, and beyond) CGMs.
Usage Benefits: Gluco-ChaserTM CGM offers the following features: (1) calibration-free operation of the sensor*; (2) 30-minute window for initial stabilization (competitors range anywhere from 3 to 12 hrs); and (3) affordable pricing, comparable to that of conventional finger-prick sensors. This package of features have yet to be implemented by current market leaders, making the Gluco-ChaserTM CGM a smarter choice for Type-2 as well as Type-1 patients.
* Currently under development
Current achievements: (1) short initial stabilization time (30 minutes); (2) long sensor stability (immersed in human plasma for 1 month); (3) animal testing (EGA A+B > 90%); (4) elimination of noise from major interferents such as ascorbic acid, acetaminophen, and maltose; (5) BGM strip sensor under development (Whole blood tested; EGA A+B = 98%; journal publication in press).
About Gluco-Chaser Inc. Gluco-Chaser Inc was launched in the USA (Redmond, WA) in 2017 as a wholly owned subsidiary of the mother company that had been formed in 2006. The founders are the lead authors of the highly cited journal publications describing non-enzymatic electrochemical detection of glucose. Shaping the future of the glucose monitoring industry has been at the forefront of the company’s missions. True to its mission, the company has optimized the relevant technologies for over a decade. The advantages of Gluco-Chaser Inc’s platform technologies make Gluco-ChaserTM a primary leader in the huge and rapidly expanding market of glucose monitoring.
Contact Gluco-Chaser Inc is looking for acquisition buyers, partners, and investors interested in our proprietary technologies and prospective products. Please contact Peter Lee firstname.lastname@example.org or email@example.com +1-425-625-6724